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Introduction
Translocation renal cell carcinoma (tRCC) is a subtype of renal cell carcinoma (RCC) that was recognized in the 2004 World Health Organization classification of renal tumors as a genetically distinct entity (1). Originally described in pediatric patients, the spectrum of the disease has recently been expanded to include adults (2) . Recent studies showed that tRCC represents one third of pediatric RCCs, up to 15% of RCCs in patients < 45 years old, and up to 5% of all RCCs regardless of age (3) (4) (5) . The hallmark of tRCC is the fusion of the TFE3 gene, located in Xp11, with various partners, including PRCC in t(X;1)(p11.2;q21), SFPQ in t(X;1)(p11.2;p34), ASPSCR1 in t(X;17)(p11.2;q25), NONO in inv(X)(p11.2q12), and CLTC in t(X;17)(p11;q23) (6) . tRCC can also be related to translocations involving the TFEB gene (7).
We and others have reported that the disease behaves differently in adult and pediatric patients (2, (8) (9) (10) . Similarly, better outcomes in young patients were reported for alveolar soft part sarcoma, a tumor characterized by ASPSCR1-TFE3 translocation (11) . Recently, we demonstrated that patients with tRCC who had metastatic disease at presentation were older (median age 36 years) and predominantly male, whereas patients who had loco-regional disease were younger (median age 16 years) and predominantly female (9) . These data are in line with previous reports, suggesting a more aggressive disease in adults, especially in men (8, 6 associations between specific chromosomal imbalances and classical clinicopathologic factors and overall survival (OS).
Patients and Methods

Patient selection and classification of cases included in single-nucleotide polymorphism (SNP)-array analysis
Tissue specimens from 21 patients with a histopathologic diagnosis of tRCC supported by TFE3 positivity on immunohistochemistry were collected after approval of the institutional review board of each of the participating centers. TFE3 and TFEB immunostaining were performed at each individual institution as previously described (7, 17) . The flow chart of patient selection, describing the different tests performed is depicted in Supplementary Figure 1 .
Among the total of 21 cases, 15 were confirmed to be tRCC by fluorescence in situ hybridization (FISH), conventional karyotyping, or reverse transcription polymerase chain reaction RT-PCR analysis for all known specific fusion partners. One patient whose tumor had classical tRCC morphology and TFEB immunohistochemical positivity was also included in the final cohort (n = 16). We collected the following clinicopathologic information for each patient: age, sex, ethnicity, tumor-node-metastasis (TNM) classification, tumor size, lymph node involvement, Fuhrman grade, and survival time (Supplementary Table 1 ). The clinico-pathologic data from 5 of the patients (numbers T31 through T35) were previously reported (9) . Four patients with positive TFE3 immunohistochemistry but negative by FISH analysis for TFE3 translocations were included in the SNP array studies as a control group.
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tissues of patients for whom we previously reported pathological features and outcome (9, 18) .
Seven of those patients had confirmed translocation by karyotyping and/or RT-PCR, and the remaining had their diagnosis confirmed by TFE3 immunostaining, as previously described (18) .
Furthermore, DNA extracted from 16 samples belonging to adjacent normal kidney of patients operated on for renal cell carcinoma were included to study LINE-1 methylation variability. DNA isolation was done using the Gentra Systems Puregene DNA purification kit according to the manufacturer's instructions. LINE-1 repetitive element, a surrogate of global DNA methylation, was assessed by pyrosequencing as described previously (19) . Assay replicates for this assay were highly correlated as previously shown (19) .
Generation of novel cell lines from adult patients
Two novel cell lines, HCR-59 and MDA-92, were derived from 2 adults treated at MD Anderson Cancer Center (MDACC), as previously reported for other RCC subtypes (20) . HCR-59 was derived from a 20-year old Caucasian female, and MDA-92 was derived from a 51-yearold Hispanic male. For both of those cell lines, karyotyping was performed according to previously published methods (21) . Spectral karyotyping (SKY) was also performed on HCR-59 by using the human chromosome HiSKY probe (Applied Spectral Imaging, Inc., Carlsbad, CA).
The tRCC cell lines UOK109 and UOK146, derived, respectively, from a 39-year-old male and a 42-year-old female (22) , were kindly provided by Dr. W. Marston Linehan (United States 8 DNA obtained from frozen tissues or from manually microdissected FFPE containing at least 70% tumor cells was quantified on a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham MA). The DNA was analyzed on Affy250KNsp SNP genotyping arrays (Affymetrix, Inc., Santa Clara, CA) following the previously reported modified protocol (24) . Loss of heterozygosity and copy number estimates were obtained by using the publicly available Copy Number Analyzer for Affymetrix GeneChip Arrays package (CNAG v3.0) (25) .
The number of genetic alterations was defined as the number of gains and losses of segmental chromosomal regions.
RNA sequencing
For 4 translocation Xp11 cases (T31, T32, T34, T1), RNA of good quality with RNA integrity number values between 8.0 and 10.0 was available. Briefly, preparation of mRNA-seq libraries for each case was performed according to Illumina procedures at the MDACC Genomic Core Facility, and sequencing was done on a HiSeq 2000 system (Illumina, Inc., San Diego, CA).
After quality control, reads were mapped and then aligned to the UCSC hg19 version of the reference genome. Gene expression counts were normalized using the RPKM (reads/Kb/Million) method (26) .
Gene set enrichment analysis (GSEA)
Gene set enrichment analysis (GSEA) is a computational method that assesses whether a defined set of genes shows statistically significant differences between 2 conditions (24). The average degree of change between the normalized RPKM values of 2 samples with partial 17q gain and 2 samples without was calculated, and genes were ranked by order of expression in the 2 samples with partial 17q gain. The list was uploaded as a pre-ranked list to GSEAv2.04 (Broad Institute, Cambridge, MA) (27) , and GSEA was performed using the default 
Mutation of TP53 and VHL genes
For the TP53 gene, mutations occurring in exons 5 to 8 were assessed using five sets of oligonucleotide primers as previously described (28) . VHL mutations were assessed using four primers pairs as previously described (29) . Overall, 12 cases with available DNA were analyzed as showed in Supplementary Figure 1 .
Statistical analysis
Associations with clinicopathologic factors were analyzed with chi-square and t test. OS was calculated from the date of nephrectomy to the date of death or last visit (censored).
Survival probabilities were estimated with the Kaplan-Meier method, and log-rank testing was applied to compare survival curves. Spearman correlation coefficient was used to assess the correlation between the LINE-1 methylation and number of genetic aberrations. All statistical tests were 2-sided and performed at the significance level of 0.05 using Prism version 5 (GraphPad Software, Inc., La Jolla, CA).
Results
Patient and tumor characteristics
Patient and tumor characteristics are summarized in supplementary Translocation carcinomas showed significant heterogeneity in cytogenomic profiles ( Figure   1 / Table 1 ). The most common alteration observed was a gain of 17q, which was present in 7 (44%) of the tumors. Less frequent alterations were gains of chromosomes 12 and 7, observed in 6 (37%) and 5 (31%) patients, respectively. The most commonly observed cytogenetic losses were of 9p in 6 (37%) patients and of 3p, 1p, 17p, and 18q, each of which occuring in 5 (31%) patients. Three of ten women in our cohort (30%) lost 1 X chromosome.
Overall, the 16 cases of tRCC with a confirmed translocation could be classified into 4 groups on the basis of their similarities to cytogenomic profiles of other renal epithelial tumors (15) .
• Group I: five cases had profiles similar to those of ccRCC, owing to 3p loss and other imbalances (including the TFEB case). Three of those 5 cases were available for histological review with 2 showing mixed clear-cell/papillary features, and one showing only clear-cell morphology.
• Group II: three cases had profiles similar to those of pRCC with gains of chromosomes 7, 12, and 17. All 3 cases showed mixed ccRCC and pRCC histology.
• Group III: five cases had novel cytogenomic profiles, i.e., not associated with those of other subsets of renal tumors.
• Group IV: three cases had a balanced chromosomal complement.
As Fig. 1 shows, tRCC tumors had heterogeneous chromosome copy number profiles. 3p loss was associated with 9p loss (P < 0.04) but not associated with the loss of 1p, 17p, or 18q (P = 0.24 for each comparison). There was no significant difference in the number of genetic alterations between patients with 3p loss and those without (11.8 vs. 6.7; P = 0.23).
Of the 7 cases (44%) that had a gain of 17q, 2 tumors had a confirmed t(X;17)(p11;q25) translocation and 1 case had a TFEB translocation. Interestingly, in four of the seven cases with 17q gain, 17p loss has been demonstrated consistent with the generation of an isochromosome 17q, or i(17q). In contrast, none of 4 cases overexpressing TFE3 but negative by FISH had gain of 17q or loss of 17p, and 2 of them had 3p loss (Supplementary Table 2 ).
Tumors of adult patients (age ≥ 18 years) showed more genetic abnormalities than tumors from younger patients (age < 18 years) (P = 0.006) ( Fig. 2A) , with no differences found in sex (P = 0.31), TNM stage (P = 0.60), and Fuhrman grade (P = 0.62).
Unsupervised clustering reveals 2 distinct groups of tRCC
To gain insights into the biology of tRCC, we performed unsupervised clustering analysis using the most frequent segmental alterations (losses or gains). That analysis revealed 2 main clusters ( Fig. 2A) . The median number of genetic alterations in cluster A was 0 (range, 0-5), compared to 14 in cluster B (range, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The 2 clusters showed no significant differences in terms of pT stage, lymph node involvement, metastasis, TNM classification, gender, and Fuhrman grade. The only statistical difference between clusters was age at diagnosis: the median age of the seven patients in cluster A was 16.7 years (range, 9.1-33.1 years), compared to 34.2 years (range, 16-54 years) for the 9 patients in cluster B (P = 0.01). Overall, 5 of the 7 (71%) patients in cluster A were younger than age 18, compared with 1 of the 9 (11%) patients in cluster B. Of note, 7 of the 10 patients who were older than 18 years had a 17q gain, but none of the 2 older patients in cluster A did.
Association between chromosomal imbalances and pathologic features and outcome
As noted above, a gain of 17q was the most frequent alteration (44%) we found in tRCC with a minimally gained region of 11.9 Mb (17q24.3-q25.3). Four of these cases had 17p deletions, with a minimally deleted region of 22.1 Mb (entire p arm), including the TP53 locus.
No associations were found between 17q gain and any other frequently occurring genetic gain or loss. The mean number of alterations in patients with 17q gain was 14.4 ± 2.4 vs. 3.7 ± 2.4 in patients without 17q gain (P < 0.003) (Fig. 2B) . In addition, patients with 17q gain were older (Fig. 2C) .
Patients with 3p loss had a higher pT stage than did those without 3p loss (P = 0.03).
However, in contrast to the 17q gain, no association was found between 3p loss and clinicopathologic variables such as age, gender, and TNM classification. Patients with 3p loss also had a shorter OS time than did those without 3p loss, with median 12.7 months vs. not reached (P = 0.001). To assess whether 3p loss was associated with VHL mutations, as is the case for ccRCC, somatic mutations of VHL were analyzed in 12 cases, but no mutations were identified.
Patients with 9p loss had more genetic alterations than did patients without 9p loss: 15.0 ± 2.3 vs. 4.3 ± 1.9 (P = 0.003). No statistically significant associations were found between 9p loss and age, gender, TNM stage classification, pT stage, lymph node involvement, or metastasis; patients with 9p loss had a shorter OS time than did those without 9p loss, with median OS of 26 months vs. 66 months. However, this difference did not reach statistical significance (P = 0.13).
Cell lines recapitulate cytogenomic profiles from tumors
We used the established cell lines UOK109 and UOK146 and the novel cell lines HCR-59
and MDA-92. The UOK109 line, which was derived from a tumor originally reported as papillary RCC, had a pRCC-like cytogenomic profile, with chromosome 7 gain (Supplementary Fig. 2A ).
In contrast, the UOK146 cell line, also derived from a pRCC tumor, had a ccRCC-like Fig. 2B ).
To assess whether the 17q gain is related to unbalanced translocation or is the result of an isochromosome 17, we performed G-banding karyotyping of the UOK146 cells. Besides a 3p loss, an i(17q) was present. This is consistent with a model in which a 17q gain in cancer often occurs as the result of i(17q) formation and is accompanied by allelic loss at 17p (Supplementary Fig. 2C ).
The results of FISH analysis for TFE3 ( Supplementary Fig. 2D ) as well as conventional karyotyping of the MDA-92 cell line (derived from patient T3) confirmed the TFE3 translocation (data not shown) and showed a near-tetraploid karyotype, with 1p and 3p losses, as is the case for the primary tumor. We also observed 2 interchromosomal translocations involving 17q that led to 17q gains (Fig. 3A) . Similarly, spectral karyotyping of the HCR-59 cell line (derived from patient T1) showed, besides 3p and 17p losses, 6 translocated chromosomes with 3 of them involving 17q (Fig. 3B) GSEA showed significant enrichment of genes located in the 17q arm as follows: 17q25
[false discovery rate (FDR) = 0.0001; P < 0.0001], 17q23 (FDR = 0.07; P < 0.001), 17q21 (FDR = 0.08; P < 0.001), 17q24 (FDR = 0.10; P < 0.001), and 17q22 (FDR = 0.10; P < 0.001) (Fig.   4A ), and no enrichment for 17p genes. Interestingly, when genes were classified according to the C6 oncogenic signature in the Molecular Signatures Database, we found enrichment for genes down-regulated by TP53 in NCI-60 panel of cell lines with mutated TP53 as compared to those classified as normal (Fig. 4B ).
As gain of 17q was frequently associated with loss of 17p, which contains the p53 tumor suppressor gene, and as p53 loss is commonly associated with a poor prognosis in various malignancies, we assessed for the presence of TP53 mutations. Sanger sequencing was thus performed on 12 tRCC including 7 cases bearing gain of 17q, but no mutation of TP53 was identified in any of those cases (not shown). Interestingly, Ingenuity Pathway Analysis identified TP53 inactivation as the top transcription regulator factor predicted to be inactivated in the two cases (RCC-T34 and RCC-T1) with concomitant partial 17q gain as compared to the two cases (RCC-T31 and RCC-T32) with balanced karyotype (Supplementary Table 3 ). Overall, there were 51 out of 89 genes whose expression direction were consistent with inhibition of TP53 (zscore= -3.84; P = 5.37 x 10 -11 ) (Fig. 4C ).
Also consistent with TP53 inactivation, GSEA showed enrichment for multiple pathways related to mitosis as follows: the M phase of the mitotic cycle (FDR = 0.10; P < 0.001), mitosis (FDR = 0.10; P < 0.001), and the M phase (FDR = 0.10; P < 0.001), in keeping with the aggressive phenotype of cases with partial 17q gain (Supplementary Figure 3A) .
KEGG (Kyoto Encyclopedia of Genes and Genomes) and BioCarta (BioCarta LLC, San
Diego, CA) pathways (C2 gene set) using GSEA and Ingenuity analysis (Ingenuity Systems, Inc., Redwood City, CA) showed consistent results with T-cell activation in the subgroup of Figure 3B) . Immunohistochemistry for CD3 and CD5 T-cell markers showed increase of T lymphocytes in the 2 cases with 17q gain (10-20%) as compared with less than 1-2% in the 2 cases without 17q gain (not shown).
LINE-1 methylation is lower in adults than in young patients (< 18 years old)
We performed LINE-1 methylation analyses in a total of 27 tRCC cases (12 of which had SNP array results. LINE-1 methylation levels correlated inversely with the number of genetic abnormalities in cases with both SNP-array and LINE-1 methylation data (Spearman's [rho] = -0.6; P = 0.04) (Fig. 5A) . Consistent with the greater number of genetic abnormalities in adult patients, in the 27-patient cohort, adults showed lower LINE-1 methylation, compared with younger patients (71.1% vs. 76.7%; P = 0.02) (Fig. 5B) . Methylation levels of normal kidney tissue showed little variability with an average methylation of 73.07% and standard variation of +/-0.50, and no association with age or gender.
Discussion
To our knowledge, this is the first study to describe cytogenomic aberrations and DNA methylation status in a cohort of pediatric, adolescent, and adult patients with translocation RCC. Our study shows cytogenomic and epigenetic heterogeneity of tRCC and unexpectedly reveals that these tumors share genomic alterations that are common to ccRCCs and pRCCs.
Our results show that tRCC tumors from young patients (< 18 years) display fewer genetic alterations and higher levels of global DNA methylation, compared to tumors from adult patients (≥ 18 years). Moreover, our data show that a partial 17q gain is frequent in tumors from adult patients, particularly in men, and this genetic lesion is associated with poor outcome.
Although the identification of significant correlations between cytogenetic alterations and histopathological subtypes of RCC is well established for common renal cancer subtypes, such as ccRCC (e.g., 3p loss) and pRCC (e.g., trisomy 7 and/or 17) (15, 30) , little is known about chromosome copy number alterations in tRCC. Here, we show that a large proportion of tRCCs present with chromosome copy number changes similar to those observed in ccRCC or pRCC, but almost 30% of them display cytogenomic profiles that cannot be related to these or characterized RCC subtypes.
Morphologic diagnosis of tRCC is challenging, especially in adult patients. Sukov et al. Alternatively, tumor initiation by the TFE3/TFEB translocation might trigger chromosomal instability pathways that resemble those in ccRCC and pRCC subtypes. Future studies are needed to clarify whether the presence of these translocations is enough to determine a tRCC diagnosis and if tumor behavior (and response to therapy) depends on the overall genomic profile. Interestingly, tRCC patients with 3p loss (ccRCC-like profile) had worse outcomes compared to those without 3p loss. In contrast, 9p loss in our study was not associated with a poor prognosis, as it is in early stage ccRCC (32) .
Another interesting finding of our study is the greater number of genetic abnormalities and the lower level of global methylation found in tRCC tumors from adult patients, compared with tumors from young patients. These data are concordant with the significant inverse correlation between the degree of genomic alterations and the LINE-1 methylation levels reported in other tumor types (39) . Although the difference in methylation levels between adult and young patients is small, it achieved statistical significance due to the robustness of the assay employed. This is demonstrated by the fact that methylation levels of normal kidneys showed little variability with an average methylation of 73.07% (+/-0.50%). Using this assay, no 
significant associations were previously found between LINE-1 methylation and age, gender or diet in colonic tissues (19) ; thus, we believe that the observed differences are related to intrinsic characteristics of tRCC in adult and young patients, rather than to age. Additional studies with a larger group of patients are necessary to confirm these findings.
The cytogenomic differences between tumors from adult and young patients were independent of classical clinicopathological prognostic factors such as TNM stage and Fuhrman grade. Although those results might be related to a small number of cases, cytogenomic array analysis in 3 of our 4 young patients with AJCC stage III-IV disease found no genetic abnormalities. Another age-related difference is that gains in 17q were identified in tumors from 70% (n = 7/10) of all our adult patients, whereas this abnormality was not found in younger patients. Patients with 17q gain were more frequently men, displayed more genetic alterations, and had worse outcomes. Five of those patients had a partial gain of 17q, whereas 2 had trisomy 17. Of interest 17q gains are rare in ccRCC and pRCC, in contrast to trisomy 7 and 17, which are very frequent in pRCC (15) . Based on our study of patient derived cell lines, 17q gains seem to arise from i(17q) and/or unbalanced translocations and complex rearrangements.
Together with G-banding and SNP results available for 3 cell lines (HCR-59, MDA-92, and UOK146), our data showed that 2 cases had multiple translocations involving 17q, leading to 17q gain concomitant with i(17q) formation in 1 case, and 1 case had only an i(17q) without other associated translocations. Two cases had breakpoints in 17p11.2 and were thus considered isodicentric chromosomes. Of note, 17p11.2 has been reported to contain a cluster region characterized by large palindromic and low copy-repeat sequences in chronic myeloid leukemia (CML), medulloblastoma with idic(17)(p11), and high hyperdiploid childhood acute lymphoblastic leukemia (40) (41) (42) (43) . This complex architecture suggests that i(17q) does not occur randomly, but rather because of susceptibility in the genomic structure. However, the reason why 17q is associated with age remains unclear; and whether adults with tRCC without a 17q Abnormalities involving 17q have been previously described in tRCC but to date 17q gain had not been recognized as a recurrent abnormality in these tumors, nor its possible association with outcomes. Among our 14 previously reported cases (9), we found one case, that of a 2-year-old girl, who had a t(5;17)(q23;q25), in addition to a t(X;17)(p11.2,17q25) leading to the ASPSCR1-TFE3 fusion, consistent with multiple translocations occurring on the 17q arm. This patient had lymph node involvement and lung metastasis at the time of her diagnosis, which is rare in pediatric cases of tRCC (9) . A recent case report of the t(X;17)(p11;q25) translocation, in a 24-year-old Japanese woman (45) , also showed the presence of a second translocation involving 17q: t(13;17)(p11;q11). Moreover, in the original report by Argani et al. that described tRCC (13), they identified a complex nonreciprocal t(X;17)(p11.2;q25), involving not only the translocation of Xp11 to 17q25 but also of 17q25 to another chromosome. Our results and these reports in the literature suggest an important role of 17q in the biology of a subset of tRCC tumors. 
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Although we did not study whether there is intratumoral heterogeneity with respect to the presence of 17q and other chromosomal abnormalities identified in this study, we have previously demonstrated that intratumoral heterogeneity at the level of chromosomal abnormalities is seen in only up to 20% of RCC cases (46), in contrast with the level of mutational heterogeneity reported by Gerlinger and collaborators (47) . However, intratumoral heterogeneity studies might be helpful to understand whether 17q is an initiating event or acquired during tumor progression, as cytogenomic heterogeneity in our prior studies is restricted to abnormalities acquired during tumor progression (46) .
In conclusion, our data show that tRCC is genetically heterogeneous and share cytogenomic profiles with other renal cell tumors, raising important questions about the role for TFE3/TFEB translocations in tumor initiation and/or progression. Furthermore, we have shown that cytogenomic and methylation differences exist between tRCC tumors arising in adult and pediatric/adolescent patients. These data may be used to develop prognostic biomarkers in tRCC patients. 
